Company news

Cynata Therapeutics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

December 2025 Quarterly Activity Report and Appendix 4C

January 28, 2026

Cynata Completes $1.2m At-The-Market Raise

January 23, 2026

Patient Enrolment Complete in Phase 2 aGvHD Clinical Trial

December 14, 2025

Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial

December 14, 2025

Positive DSMB Review in Phase 1/2 Kidney Transplant Trial

December 3, 2025

Final Patient Visit Complete in Phase 3 Osteoarthritis Trial

November 23, 2025

Cynata Receives $1.7m R&D Tax Incentive Refund

November 5, 2025

September 2025 Quarterly Activity Report and Appendix 4C

October 31, 2025

Appendix 4E & Annual Report

August 28, 2025

At-the-Market Subscription Agreement

August 21, 2025

June 2025 Quarterly Activity Report and Appendix 4C

July 30, 2025

CYP-001s FDA Approval Pathway Not Impeded

May 16, 2025

March 2025 Quarterly Activity Report and Appendix 4C

April 24, 2025

Publication comparing Cymerus MSCs to other MSCs

February 4, 2025

Quarterly Activity Report & Appendix 4C

January 29, 2025

First Kidney Transplant Trial Patient Treated

December 11, 2024

Cynata secures commitments for $8.1m institutional placement

December 5, 2024

Demonstrated Safety & Efficacy in DFU Clinical Trial

December 5, 2024

Trading Halt

December 3, 2024

Cynata Receives $1.88m R&D Tax Incentive Refund

November 26, 2024

Study of Cymerus MSCs in Pulmonary Fibrosis Published

August 8, 2024

Cynata to Acquire IP from Tekcyte

July 1, 2024

Further GvHD Clinical Data Published in Nature Medicine

May 22, 2024

DFU Clinical Trial Enrolment Complete

April 7, 2024

EU Approval for Phase 2 CYP-001 Trial in GvHD

March 19, 2024

First Patient Treated in Phase 2 GvHD Trial

March 4, 2024

Encouraging Initial Data from CYP-006TK DFU Trial

February 25, 2024

Recruitment Completed in Phase 3 OA Clinical Trial

December 12, 2023

Phase 2 Trial of CYP-001 in aGvHD Approved in Turkey

December 6, 2023

Cynata Receives $2.315m R&D Tax Incentive Refund

November 13, 2023

Approval of Clinical Trial of CYP-001 in Kidney Transplant

August 20, 2023

Phase 2 Trial of CYP-001 in aGvHD Open for Recruitment

August 9, 2023

Strategic Review of Cynata Clinical Development Portfolio

July 24, 2023

Cynata announces CEO succession and Board changes

June 29, 2023

Cynata Completes Oversubscribed Share Purchase Plan

May 10, 2023

Share Purchase Plan Booklet & Option Prospectus

April 19, 2023

Ethics Committee Approval for Proposed aGvHD Phase 2 Trial

April 11, 2023

Capital Raising Presentation

April 5, 2023

Cynata completes $5.0m Placement and launches SPP

April 5, 2023

Cynata Adds New Sites for DFU Clinical Trial

March 16, 2023

Cynata Receives IRB Approval for aGvHD Clinical Trial

January 29, 2023

Notice of Acceptance for Cynata Australian Patent

January 9, 2023

Cynata Receives $1.65m R&D Tax Incentive Refund

December 4, 2022

Notice of Allowance for Cynata US Patent

November 10, 2022

New Kidney Transplantation Clinical Trial for Cynata & LUMC

November 1, 2022

Notice of Allowance for Australia & Canada Cymerus Patents

October 16, 2022

Successful Completion of Planned DSMB Review of DFU Trial

October 11, 2022

Grant Award to Fund Study of Cynata MSCs in Heart Disease

September 25, 2022

Pipeline Update Following Strategic Portfolio Review

August 11, 2022

Further data supports potency of Cynata MSCs

June 13, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 39 decks. Every deck is listed under its year.